Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Google Secures Pentagon AI Deal for Classified Projects 
BOTHELL, Wash., April 20, 2017 -- Alder BioPharmaceuticals®, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its first quarter 2017 financial and operating results after the close of U.S. financial markets on Thursday, April 27, 2017. Alder management will host a conference call and live audio webcast to discuss the results and provide a general business update at 5:00 p.m. ET the same day.
The live call may be accessed by dialing (877) 430-4657 for domestic callers or (484) 756-4339 for international callers, and providing conference ID number 94734332. The webcast will be broadcast live on the investors section of Alder’s website at www.alderbio.com and will be available for replay following the call for 30 days.
About Alder BioPharmaceuticals®
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contacts: David Schull Russo Partners, LLC (212) 845-4271 (646) 942-5627 [email protected] Investor Relations Contact: David Walsey Alder BioPharmaceuticals® Inc. (425) 408-8032 [email protected]
